Clinical trial

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT02222948

Study summary

ClinicalTrials.gov

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Vatelizumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo (for Vatelizumab) Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-09-01

PhasePHASE2

Conditions

Relapsing-remitting Multiple Sclerosisverified · MONDO: relapsing-remitting multiple sclerosis

Interventions

VatelizumabDRUG

Placebo (for Vatelizumab)DRUG

Sponsors & collaborators

Genzyme, a Sanofi Companylead sponsor

Mapped research locations

Saint PetersburgRussia3 MoscowRussia2 LodzPoland2 LublinPoland2 Nizhny NovgorodRussia2 San AntonioTexas, United States1 SeattleWashington, United States1 TampaFlorida, United States1 Washington D.C.District of Columbia, United States1 PhoenixArizona, United States1 Salt Lake CityUtah, United States1 WarsawPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02222948 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.